Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 22, 2011

Primary Completion Date

September 5, 2018

Study Completion Date

September 5, 2018

Conditions
Myeloproliferative Diseases
Interventions
DRUG

Ruxolitinib

15 mg by mouth twice daily (BID), continuously in 28-day cycles.

DRUG

Lenalidomide

5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.

DRUG

Prednisone

"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01375140 - Ruxolitinib and Lenalidomide for Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter